REGENCY: Obinutuzumab’s Promise for Lupus Nephritis
Feb 28, 2025•54 min•Season 4Ep. 32
Episode description
Join Dr Raquel Faria and Professors Richard Furie and Maria Dall’Era as they discuss the results of the phase 3 REGENCY trial of obinutuzumab for the treatment of lupus nephritis.This episode explores what obinutuzumab could mean for the future management of lupus nephritis.
Disclaimer: During Lupus Academy podcast episodes, participants may refer to off label use of medicines forpatients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.
For the best experience, listen in Metacast app for iOS or Android
